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Background: Metabolic syndrome (MetS) is a cluster of conditions that occur together, increasing the risk of heart
disease, stroke and diabetes. Since pathways implicated in different diseases reveal surprising insights into shared
genetic bases underlying apparently unrelated traits, we hypothesize that there are common genetic components
involved in the clustering of MetS traits. With the aim of identifying these common genetic components, we have
performed a genetic association study by integrating MetS traits in a continuous MetS score.
Methods: A cross-sectional study developed in the context of the Portuguese Component of the European Health
Examination Survey (EHES) was used. Data was collected through a detailed questionnaire and physical examination.
Blood samples were collected and biochemical analyses were performed. Waist circumference, blood pressure, glucose,
triglycerides and high density lipoprotein cholesterol (HDL) levels were used to compute a continuous MetS score,
obtained by Principal Component Analysis. A total of 37 single nucleotide polymorphisms (SNPs) were genotyped and
individually tested for association with the score, adjusting for confounding variables.
Results: A total of 206 individuals were studied. Calculated MetS score increased progressively with increasing number
of risk factors (P < 0.001). We found a significant association between CYP2C19 rs4244285 and the MetS score not
detected using the MetS dichotomic approach. Individuals with the A allelic variant seem to be protected against
MetS, displaying a lower MetS score (Mean difference: 0.847; 95%CI: 0.163-1.531; P = 0.015), after adjustment for age,
gender, smoking status, excessive alcohol consumption and physical inactivity. An additive genetic effect of GABRA2
rs279871, NPY rs16147 and TPMT rs1142345 in the MetS score variation was also found.
Conclusions: This is the first report of a genetic association study using a continuous MetS score. The significant
association found between the CYP2C19 polymorphism and the MetS score but not with the individual associated
traits, emphasizes the importance of lipid metabolism in a MetS common etiological pathway and consequently on
the clustering of different cardiovascular risk factors. Despite the sample size limitation of our study, this strategy can be
useful to find genetic factors involved in the etiology of other disorders that are defined in a dichotomized way.
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Metabolic syndrome (MetS) is a cluster of conditions —
increased blood pressure, high blood glucose level, ex-
cess body fat around the waist and abnormal cholesterol
levels — that occur together. It is strongly associated
with cardiovascular diseases (CVD) and Type 2 Diabetes,
increasing the risk of developing these disorders 2 and 5
fold, respectively [1]. MetS incidence and prevalence
have clearly been rising worldwide, largely because of
the increase in obesity rates, sedentary lifestyles and
aging populations, and it is currently considered a sig-
nificant public health problem [2]. In Portugal, the MetS
prevalence, estimated for 2008, was 27.5% with regional
variations, being highest in the Alentejo (30.99%) and
lowest in the Algarve (24.42%) [3].
Due to the existence of multiple definitions consider-
ing different categorical cut-points, a consensus defin-
ition for MetS clinical diagnosis has been recently
proposed. According to this definition, MetS is diag-
nosed when there are present at least three of the fol-
lowing five MetS features: abdominal obesity, elevated
blood pressure, dyslipidemia (elevated triglycerides and
low levels of high-density lipoprotein cholesterol), and
hyperglycemia. Medication for any of these features is
also considered as an indicator in the criteria for clinical
diagnosis of MetS [4].
As a complex condition, MetS results from a complex
interplay between many genetic and environmental fac-
tors. Lifestyle risk factors, particularly caloric excess diet
and physical inactivity, seem to play an important role in
MetS condition [5] but there is also evidence that its
traits are highly heritable [6]. In a recent review of
genome-wide association studies (GWAS), most of the
single nucleotide polymorphisms (SNPs) associated with
MetS traits are SNPs involved in lipid metabolism, like
FTO rs9939609, TCF7L2 rs7903146, IL6 rs1800795,
APOA5 rs662799, APOC3 rs2854117 and CETP rs708272
[7]. However, the identified variations explain only a very
small fraction of disease burden in the population at large,
suggesting that other genetic variants and interacting en-
vironmental factors are contributing to MetS susceptibil-
ity. Another important issue is that GWAS have identified
numerous loci influencing metabolic risk traits individu-
ally, but to date, no loci have been found affecting the en-
tire spectrum of MetS traits [8,9]. These limitations may
be due to the highly heterogeneous groups originated by
the traditional dichotomic MetS approach, reflecting asso-
ciations with particular individual traits. In this context,
and given that comparison of pathways and processes im-
plicated in different diseases are revealing surprising in-
sights into the shared genetic bases underlying apparently
unrelated traits [10], our main hypothesis is that there is a
common genetic component underlying the clustering of
MetS traits.Although the consensus dichotomized definition pre-
viously described remains useful for clinical practice, it
loses statistical power and information when performing
association studies. There are multiple evidences that a
continuous outcome increases the statistical power in
genetic association studies instead of a dichotomous
phenotype [8], and consequently for genetic epidemio-
logical approaches, a continuous MetS score, obtained
by integrating all MetS traits, would be a more appropri-
ate and valid alternative to study the underlying risk fac-
tors responsible for that condition [11]. Therefore, taking
these issues into account, the purpose of this study was to
identify genetic factors associated with MetS, using a
Principal Component Analysis (PCA) derived continuous
MetS score, which has been previously validated [11], to
perform a genetic association study using SNPs in candi-
date genes related to MetS features, like glucose/insulin
homeostasis, cardiovascular regulation, body mass index
and lipid/drug metabolism.
Methods
Study design and participants
We have performed a cross-sectional study as designed
for the pilot study of the Portuguese Component of the
European Health Examination Survey (EHES) project
[12,13]. This pilot study was conducted between 2010
and 2011, in the population covered by the São Brás de
Alportel (Algarve) Health Center, constituted by 11089
individuals (2.6% of the total Algarve population). It
consisted on an observational and descriptive epidemio-
logical study with data collected through a detailed ques-
tionnaire (including socio-demographic factors, health
state and health determinants) and physical examination.
A blood sample for further biochemical analysis was also
collected. Participants were selected using a simple ran-
dom sampling scheme from the National Health System
card number database, which covers over 99% of the total
population from the São Brás de Alportel Health Center
users. All participants were given a brief description of the
objectives of the study, after which they signed an
informed consent form. The study protocol was approved
by the Ethics Committee of National Health Institute
Doctor Ricardo Jorge and by the National Commission for
Data Protection.
Measurements and blood sample collection
Blood pressure, anthropometric (weigh, height and
waist circumference) and biochemical (high density
lipoprotein cholesterol (HDL), triglycerides (TG) and
glucose) measurements were performed in accordance
with the recommendations proposed by FEHES –
“Feasibility of a European Health Examination Survey”
[14]. Genomic DNA was isolated from whole blood con-
taining EDTA according to standard methods [15].
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The MetS score was calculated by principal component
analysis (PCA) with varimax rotation, as previously de-
scribed [11]. We have considered six quantitative MetS
risk factors (waist circumference, diastolic blood pres-
sure (DBP), systolic blood pressure (SBP), glucose, TG
and HDL plasma levels) assuming the newly harmonized
diagnostic criteria of the MetS [4].
Shapiro-Wilk test was used to assess the normality of
the MetS quantitative risk factors. Those non-normal
distributed were normalized (SBP, Glucose, HDL and
TG were normalized using log10[log10(SBP)], 1/[log10
(Glucose)]10, [ln(HDL)]2 and log10[log10(TG)] respect-
ively). We have used the first and second principle com-
ponents (PC) which represent large fractions of MetS
variance (considering eigenvalues >1.0). A final MetS
score was computed by summing the first two individual
PC scores, weighted by the relative contribution of each
principal component in the explained variance. A higher
MetS score indicates a less favorable MetS profile.
Validity of the MetS score was tested using the ANOVA
for trend analysis. T-Test and ANOVA were also used to
test mean difference values of the MetS score between
groups of risk factor categories. The consensus definition
recently proposed for MetS clinical diagnosis [4] was used
to categorize individuals. According to this definition,
MetS is diagnosed when there are present at least three of
the following five MetS features: elevated waist circumfer-
ence (men ≥94 cm, women ≥80 cm); low HDL cholesterol
(men < 40 mg/dL, women < 50 mg/dL); elevated TG
(≥150 mg/dL); elevated BP (≥130/85 mmHg); and elevated
glucose levels (≥100 mg/dL). Medication for any of these
features is also considered as alternative indicator in the
criteria for diagnosis of MetS.
SNP selection and genotyping
To test the association between the MetS score variation
and SNPs in different candidate genes potentially in-
volved in the MetS etiology, we have selected SNPs
based on their involvement in metabolic-related pheno-
types. In order to capture the maximum variation with
minimum genotyping effort, we have selected those that
were haplotype-tagging SNPs and that represented a val-
idated functionally relevant variation, reported in the
OMIM database. Consequently, we have genotyped 37
SNPs: 13 SNPs in genes involved in glucose/insulin homeo-
stasis CDKAL1 rs7754840, CDKN2A/B rs10811661, HHEX
rs1111875, IGF2BP2 rs4402960, IL6 rs1800795, KCNJ11
rs5219, KCNQ1 rs2237892, MTNR1B rs10830963, PPARG
rs1801282, SLC30A8 rs13266634, TCF7L2 rs7903146,
ADCY5 rs11708067 and KCNQ1 rs231362), 10 SNPs in
genes involved in body mass index (GNPDA2 rs10938397,
MTCH2 rs10838738, NPC1 rs1805081, PTER rs10508503,
SH2B1 rs7498665, FTO rs9939609, ADRB3 rs4994,GABRA2 rs279871, NPY rs16147, TMEM18 rs6548238),
7 SNPs in genes involved in cardiovascular system regula-
tion (ACE rs4646994, NOS1AP rs12143842, ADRB1
rs1801252, ADRB2 rs1042714, NOS3 rs1799983, NOS3
rs2070744) and 7 involved in drug/lipid metabolism (APOE
rs7412, LDLR rs2228671, CYP2C8 rs10509681, CYP2D6
rs16947, CYP2C19 rs4244285, TPMT rs1142345). All SNPs
were genotyped by Sequenom MassARRAY platform
except for seven (ACE rs464699, ADRB1 rs1801252,
ADRB2 rs1042713, CYP2C8 rs10509681, CYP2C9
rs1799853, CYP2D6 rs16947 and NOS3 rs2070744)
that were genotyped by Polymerase Chain Reaction
(PCR) followed by Restriction Fragment Length Poly-
morphism (RFLPs) analysis (Additional file 1: Tables
S1 and S2).
Statistical analysis
The statistical analysis was performed using IBM SPSS
statistics 20. P-values < 0.05 were considered to be statis-
tically significant. T-test and Mann-Whitney test were
used to access differences of quantitative variables ac-
cording to their adherence to the normal distribution,
evaluated by the Shapiro-Wilk test. Proportions were
compared using χ2 tests.
All SNPs were tested for Hardy Weinberg Equilibrium
using the Hardy Weinberg R package [16], based on the
χ2-test. The association between the MetS score and the
isolated SNPs was tested by T-test. Subsequent correc-
tion for multiple comparisons was performed using the
Bonferroni method. The association between the MetS
categorized groups (participants with MetS versus partic-
ipants without MetS) with selected SNPs was also per-
formed using χ2-test. Individual association analysis
between each MetS quantitative risk factor and the se-
lected SNPs were also performed using either T-test or
Mann-Whitney test, according to their adherence to the
normal distribution. Lifestyle risk factors (smoking sta-
tus, excessive alcohol consumption, physical inactivity
and unhealthy diet) were also individually tested for as-
sociation with the MetS score, using the T-test.
ANOVA for trend (P < 0.05) was used to assess linear-
ity between the MetS score and the number of genetic
risk factors, testing for additive genetic effects of risk
variants in the increasing of MetS score values.
General linear model analysis (GLM) was used to test
MetS score differences between subjects with different
genotypes after adjusting for confounding variables such
as age, gender, smoking status, excessive alcohol con-
sumption, physical inactivity and unhealthy diet. Smok-
ing status and excessive alcohol consumption were
defined as previously described [17]. Inadequate physical
activity was defined as practice of a regular physical ac-
tivity such as running, cycling or other, in order to feel
tired, less than once a week. Unhealthy diet was defined
Gaio et al. Diabetology & Metabolic Syndrome 2014, 6:23 Page 4 of 10
http://www.dmsjournal.com/content/6/1/23as absence of fruit or vegetables consumption on the day
before the interview. Only variables contributing more
than 5% for the MetS score variation were considered in
the model.Results
Population characteristics
From the 221 recruited participants, we have excluded
those with missing blood samples or missing values for
the analyzed parameters (n = 15). The final study popula-
tion consisted on 206 participants, 87 (42.2%) men and
119 (57.8%) women. The participants’ age ranged from
26 to 91 years, being the mean value 56.43 ± 16.23. The
general characteristics of the participants included in
this study are shown in Table 1.Table 1 General characteristics of the participants
Participants (n = 206)
Men 42.23% (35.49-48.98%)
Women 57.77% (51.03-64.50%)
Age (years ± SD) 56.43 ± 16.23
MetS prevalence1 46.12% (39.31-52.92%)
MetSscore 0.00 ± 1.41
MetS risk factors (Mean ± SD):
Waist circumference (cm) 95.50 ± 12.56
DBP (mmHg) 80.67 ± 9.96
SBP (mmHg) 131.72 ± 20.02
HDL (mg/dL) 53.51 ± 13.33
TG (mg/dL) 107.71 ± 60.29
Glucose (mg/dL) 103.29 ± 33.91
MetS related diseases
Hypertension 26.21% (20.21-32.22%)
Type 2 Diabetes 7.3% (3.73-10.83%)
Hypercholesterolemia 12.6% (8.09-17.16%)
Total 46.12% (39.31-52.92%)
Medication2 43.20% (36.44-49.97%)
Lyfestyle risk factors
Smokers 17.96% (12.72-23.20%)
Excessive alcohol consumption 8.74% (4.88-12.59%)
Inadequate physical activity 59.71% (53.01-66.41%)
Unhealthy diet 2.92% (29.37-42.47%)
Data is presented as mean ± standard deviation for continuous variables and
% (95%CI) for proportions.
1For the metabolic syndrome definition, the newly harmonized diagnostic
criteria was used [4].
2Medication for hypertension, type 2 diabetes and hypercholesterolemia
was considered.
Abbreviations: CI Confidence interval, MetS metabolic syndrome, DBP diastolic
blood pressure, SBP systolic blood pressure, HDL high density lipoprotein
cholesterol, TG triglycerides.We found differences between the frequencies of auto-
reported MetS related chronic diseases confirmed by the
family general practitioner (Table 1) and those obtained if
we considered the correspondent parameters measured in
this study, although they did not reach significance. We
have found 26.21% auto-reported hypertensive partici-
pants, based on information collected by the question-
naire, compared to 39.32% of participants who have values
of measured blood pressure above 140/90 mmHg, the cut-
off value for hypertension definition. There are also 7.3%
auto-reported diabetic participants, but 17.48% of the par-
ticipants have levels of glucose above 110 mg/dL, the cut-
off used in pre-diabetes diagnosis. The prevalence of MetS
was 46.12%, assuming the newly harmonized definition
(Figure 1). The MetS components prevalences’ are present
in Figure 1, taking into account the most restrictive cut-
off points [4].Continuous MetS score calculation by PCA
In the total sample, from PCA considering the six quan-
titative MetS risk factors, we are able to explain 63.35%
of these six components variance (PC1 and PC2 ex-
plained 35.42% and 27.43% of the variance, respectively).
The measured correlations between each MetS risk fac-
tor and both principal components are presented in
Table 2. BP, waist circumference and glucose levels are
the components contributing more to PC1. For PC2, the
main contributors are TG and HDL levels. No significant
differences were found when subjects treated with medi-
cation for hypertension, hypercholesterolemia and dia-
betes were excluded from the analysis. In fact, medicated
participants maintain altered values for the six quantita-
tive MetS score risk factors and have higher MetS score
values in comparison with non medicated participants,
suggesting a medication inefficacy or absence of medica-
tion compliance.
The MetS score adequacy and validity is shown in
Figure 2A. As expected, this score increases progres-
sively with increasing numbers of risk factors (ANOVA
test for linear trend, P < 0.001). As observed, the MetS
score is clearly higher in subjects with MetS versus subjects
without (0.97 ± 1.10 versus -0.83 ± 1.09; T-test P <0.001),
when we categorize individuals based on the dichotomic
MetS definition (Figure 2B).Genotyping data
The descriptive statistics regarding the tested SNPs are
described in Table 3. Minor allele frequencies (MAF)
range from 0.027 to 0.491. No significant differences
were found between the European MAF described in
NCBI database [18] and the obtained MAF of the
markers for the population under study. All SNPs are in
Hardy-Weinberg equilibrium (P >0.05).
Figure 1 MetS and its components prevalence. Participants medicated for hypertension, hypercholesterolemia and diabetes were also
accounted. Error bars represent the 95% confidence intervals. Abbreviations: MetS, metabolic syndrome; DBP, diastolic blood pressure; SBP,
systolic blood pressure; HDL, high density lipoprotein cholesterol; TG, triglycerides. (*For the MetS prevalence calculation, the newly harmonized
definition was considered [4]).
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Assuming a dominance model, a significant association was
found between the MetS score and the following SNPs:
CYP2C19 rs4244285 (P = 4.9×10-4), GABRA2 rs279871 (P=
0.018), NPY rs16147 (P = 0.029) and TPMT rs1142345
(P = 0.003). Considering the sample size and the allelic
frequency of the four significant associated SNPs:
CYP2C19 rs4244285, GABRA2 rs279871, NPY rs16147,
TPMT rs1142345, this study has 80% power to detect a
mean difference of 0.642, 0.598, 0.612 and 1.132 re-
spectively, in the MetS score variation. Regarding the
CYP2C19 rs4244285 SNP, individuals included in the
GA + AA genotype group seem to be protected against
MetS, displaying a lower MetS score (Mean difference:
0.792; 95%CI: 0.351-1.233; P < 0.001) (Table 4). After
Bonferroni correction for multiple testing, the associ-
ation between the MetS score and the CYP2C19 rs4244285
remains significant (P = 0.018). Within both genotype
groups, medicated individuals display higher MetSTable 2 Correlation coefficients between the normalized
components of MetS and the two principal components
obtained from PCA
MetS normalized components Coeficient correlation
PC1 PC2
Waist circumference 0.650 0.255
DBP 0.771 0.320
SBP 0.826 0.057
Glucose -0.598 0.147
HDL 0.079 -0.885
TG 0.305 0.818
Abbreviations: DBP diastolic blood pressure, SBP systolic blood pressure,
HDL high density lipoprotein cholesterol, TG triglycerides, PC1 principal
component 1, PC2 principal component 2.score values than non medicated ones, although not
reaching significance.
Despite the fact that associations of the three SNPs
(rs279871, rs16147, rs1142345) in the GABRA2, NPY
and TPMT genes, with the MetS score do not remain
significant after multiple testing correction, we can ob-
serve an additive genetic effect of these variants in the
MetS score (Figure 3A), since it increases with the
growing number of genetic risk factors (ANOVA for
trend P < 0.001). Moreover, this additive genetic effect
is age independent, as shown in Figure 3B.
No association was found between the individual MetS
quantitative risk factors (waist circumference, BP, glu-
cose, TG and HDL blood levels) and the selected SNPs.
Similarly, no association was found between MetS using
the dichotomic definition (participants with MetS versus
participants without MetS) and the analyzed SNPs. No
association was found between the MetS score and the
selected lifestyle risk factors.
General linear model analysis
Using general linear model analysis, we found that differ-
ences on the MetS score between subjects with GG geno-
type and GA+AA genotype on the CYP2C19 rs4244285
remain significant after adjustment for age, gender, smoking
status, excessive alcohol consumption and physical inactiv-
ity (Mean difference: 0.847; 95%CI: 0.163-1.531; P = 0.015).
The variable unhealthy diet was discarded since it contrib-
utes less than 5% for the MetS score variation. General lin-
ear model analysis was also performed for the other
associated SNPs: GABRA2 rs279871 (Mean difference:
0.597; 95%CI: 0.053-1.247; P = 0.071), NPY rs16147 (Mean
difference: 0.854; 95%CI: 0.175-1.532; P = 0.014) and TPMT
rs1142345 (Mean difference: 0.850; 95%CI: 0.086-1.787;
P = 0.075), assuming the adjustment for the same variables.
Figure 2 Mets score validity. A MetS score variation according to the number of risk factors (ANOVA for trend P < 0.001). B Comparison
between the affected versus unaffected participants (T-test P < 0.001). The consensus MetS definition was considered to define the affection
status MetS groups [4].
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GWAS have identified common variants of modest and
small-effect size at hundreds of loci for common chronic
disorders but a substantial fraction of heritability re-
mains unexplained [34]. Given that GWAS performed
on MetS traits, using a traditional dichotomic definition
indicates that only a small portion of the variation in
these traits can be explained by the reported common
genetic variants, our aim was to identify genetic risk fac-
tors involved in MetS etiology using a quantitative
phenotype. To achieve our goal we have tested the asso-
ciation between a group of biologically relevant SNPs in
order to seek positive genetic associations with a con-
tinuous MetS score, obtained by PCA, instead of the di-
chotomized MetS definition. We believe that, using a
continuous MetS score based on PCA to address the
issue of genetic susceptibility to MetS and its clustering
associated traits, will increase the statistical power and
unravel the missing heritability. In fact, the MetS score
based on this approach was able to explain over 63.0%
of the phenotype.
In this study, we have found a significant association
between the MetS score and the CYP2C19 rs4244285.
Individuals carrying the A allelic variant have a lower
MetS score, suggesting that these genotypes are confer-
ring protection against MetS. Most importantly, the dif-
ferences on the MetS score between subjects with GG
genotype and GA +AA genotype on the CYP2C19
remained significant after adjustment for age, gender,
smoking status, excessive alcohol consumption and
physical inactivity, which are important confounding fac-
tors, suggesting a pivotal role of this gene in metabolic
regulation.
Regarding the CYP2C19 gene polymorphisms, most of
the studies performed to date focus on the altered drugmetabolism [35] and little importance has been given to
its role on lipid metabolism involvement. It is known
that the functional enzyme product of the CYP2C19
gene also metabolizes important endogenous substrates,
namely arachidonic acid, a n-6 unsaturated fatty acid, to
produce epoxyeicosatrienoic (EETs) compounds which
generally possess vasodilating, anti-inflammatory, anti-
apoptotic, anti-thrombotic, natriurectic and cardioprotec-
tive effects [36]. On the other hand, CYP2C19 rs4244285
consists in an aberrant splice site, generating a truncated
non-functional protein, without catalytic activity [30]
which has been shown to be associated with increased ad-
verse cardiovascular events in patients medicated with
clopidogrel [37]. This hypothesis is in accordance with our
results, given that, within the GA+AA genotype group,
medicated individuals display a higher MetS score than
non medicated ones. However, further studies will be ne-
cessary to clarify whether this variant is causal or if it is in
linkage disequilibrium with the true causal variant.
Given that CYP2C19 is a highly polymorphic gene,
with at least 19 allelic variants reported [38], we have to
consider the potential coexistence of other variants that
could compensate this defective allele by overexpressing
it. Actually, a recently described gain of function allele
in CYP2C19 gene (rs12248560) is a regulatory poly-
morphism enhancing CYP2C19 expression with poten-
tial to compensate the CYP2C19 rs4244285 defective
variant [39]. We expect that, with the use of next gener-
ation sequencing technologies, we will be able to further
dissect genetic variation present in this gene and clarify
the relative contribution of each variant to the CYP2C19
actual function.
We have also found an association between the MetS
score and SNPs at the GABRA2, NPY and TPMT genes.
Despite the fact that these associations do not remain
Table 3 List of SNPs selected in the present study
Mechanisms Gene NCBI ID Alteration Reference Control Obtained HWE
MAF1(N) MAF(N) P-value2
Glucose/insulin homeostasis CDKAL1 rs7754840 C→ G [19] 0.336 (226) 0.286 (206) 0.456
CDKN2A/B rs10811661 C→ T [19] 0.199 (226) 0.201 (206) 0.056
HHEX rs1111875 A→ G [19] 0.416 (226) 0.371 (206) 0.558
IGF2BP2 rs4402960 G→ T [19] 0.280 (118) 0.272 (206) 0.422
IL6 rs1800795 C→ G [19] 0.465 (226) 0.337 (206) 0.917
KCNJ11 rs5219 C→ T [19] - 0.333 (206) 0.532
KCNQ1 rs2237892 C→ T [19] 0.075 (226) 0.051 (206) 1.000
MTNR1B rs10830963 C→ G [20] 0.300 (120) 0.223 (206) 0.264
PPARG rs1801282 C→ G [19] 0.076 (118) 0.093 (205) 1.000
SLC30A8 rs13266634 C→ T [19] 0.239 (226) 0.286 (206) 0.761
TCF7L2 rs7903146 C→ T [19] 0.279 (226) 0.303 (205) 0.256
ADCY5 rs11708067 A→ G [20] 0.226 (226) 0.199 (206) 0.835
KCNQ1 rs231362 C→ T [19] 0.482 (112) 0.234 (128) 0.214
Cardiovascular regulation ACE rs4646994 Ins/Del [21] - 0.420 (206) 0.171
NOS1AP rs12143842 C→ T [22] 0.188 (224) 0.265 (206) 0.827
ADRB1 rs1801252 A→ G [23] - 0.108 (206) 0.711
ADRB2 rs1042714 C→ G [24] 0.467 (120) 0.407 (204) 0.898
ADRB2 rs1042713 A→ G [24] 0.358 (226) 0.362 (206) 0.903
NOS3 rs1799983 G→ T [24] 0.342 (120) 0.417 (206) 0.072
LDLR rs2228671 C→ T [25] 0.106 (226) 0.124 (206) 1.000
NOS3 rs2070744 C→ T [24] - 0.451 (206) 0.892
Body mass Index GNPDA2 rs10938397 A→ G [26] 0.446 (112) 0.481 (206) 0.309
MTCH2 rs10838738 A→ G [26] 0.363 (226) 0.282 (206) 0.855
NPC1 rs1805081 A→ G [26] 0.467 (120) 0.288 (206) 0.385
PTER rs10508503 C→ T [26] 0.092 (218) 0.075 (206) 1.000
SH2B1 rs7498665 A→ G [26] 0.382 (226) 0.303 (206) 0.483
FTO rs9939609 A→ T [26] 0.449 (118) 0.361 (205) 0.396
ADRB3 rs4994 C→ T [27] 0.088 (226) 0.090 (205) 1.000
GABRA2 rs279871 A→ G [28] - 0.434 (206) 0.376
NPY rs16147 A→ G [29] 0.491 (226) 0.450 (206) 0.222
TMEM18 rs6548238 C→ T [26] 0.150 (220) 0.127 (205) 0.542
Lipid/Drug metabolism APOE rs7412 C→ T [25] - 0.027 (161) 1.000
CYP2C8 rs10509681 C→ T [30] 0.137 (226) 0.129 (206) 0.750
CYP2C9 rs1799853 C→ T [30] 0.104 (106) 0.138 (206) 0.750
CYP2D6 rs16947 A→ G [31] - 0.393 (206) 0.845
CYP2C19 rs4244285 G→ A [32] 0.155 (116) 0.129 (206) 1.000
TPMT rs1142345 A→ G [33] 0.027 (226) 0.032 (205) 1.000
1Values referring to the HAPMAP-CEU population, available in the NCBI database [18].
2P-values were obtained by “HardyWeinberg” R package, based on the χ2 -test.
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http://www.dmsjournal.com/content/6/1/23significant after multiple testing correction, likely due to
the lack of statistical power, they might represent an
additive genetic effect that should be taken in consider-
ation in the etiology of MetS. The genes NPY and
GABRA2 have been previously found associated withobesity and food intake, being involved in multiple cen-
tral nervous system functions regulation [40-42], while
TPMT has an important role in drug metabolism [43].
Given these results, we hypothesize that CYP2C19
rs424428 might be involved in a common pathway, the
Table 4 SNPs significantly associated with MetS score
Gene Genotype n MetS score Mean difference 95%CI P-valuea Corrected P-valueb
CYP2C19 GG 156 0.192 ± 1.380 0.792 0.351-1.233 0.00049 0.018
rs4244285 GA + AA1 50 -0.600 ± 1.362
GABRA2 AA 63 0.350 ± 1.374 0.504 0.087-0.921 0.018 0.670
rs279871 GA + GG2 143 -0.154 ± 1.409
NPY AA 58 0.342 ± 1.606 0.476 0.048-0.904 0.029 0.999
rs16147 GA + GG3 148 -0.134 ± 1.313
TPMT AA 192 -0.080 ± 1.375 1.199 0.413-1.984 0.003 0.109
rs1142345 GA 13 1.119 ± 1.601
aT-test was used to compare MetS score mean values between the two groups.
bCorrected P-values were obtained using the Bonferroni test to multiple testing correction.
1The GA + AA group consists on 3 AA and 47 GA individuals.
2The GA + GG group consists on 36 AA and 107 GA individuals.
3The GA + GG group consists on 37 AA and 111 GA individuals.
The MetS score is presented as mean ± SD.
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http://www.dmsjournal.com/content/6/1/23deregulation of which, in addition to other specific gen-
etic factors, may lead to the different MetS associated
traits. This hypothesis is corroborated by the fact that,
when we test associations between each MetS quantita-
tive risk factor (waist circumference, BP, glucose, TG
and HDL blood levels) and the selected candidate SNPs,
no association was found. This finding suggests that
there is a common basic pathway involving variants in
CYP2C19 alone or in association with other genes that
may lead to the development of MetS and associated
traits, similarly to what has been described for the HLA
or CTLA4 genes in the development of different auto-
immune disorders [44].
Despite the fact that, further association and func-
tional studies are necessary to highlight the role of
CYP2C19 in MetS etiology, we think that these results
may contribute to the identification of new therapeuticFigure 3 Additive genetic effects of the SNPs (GABRA2 rs279871, NPY
genotypes in the MetS score values. MetS score increases with increasing n
B- Additive genetic effect representation. Each line represents a different n
allele for each variant to be at risk. We have considered the 4 significantly
rs279871, NPY rs16147 and TPMT rs1142345. No individuals with 4 risk genotargets that may be useful in the treatment of the differ-
ent clustered traits instead of treating them individually.
Novel therapies targeted at these newly identified genes
may be developed and consequently improve the out-
come of patients affected by this disorder.
Conclusions
Our study represents an integrative approach to identify-
ing genetic risk factors involved in MetS etiology,
through a continuous MetS score obtained by PCA. This
score alone explains over 63.0% of the phenotype, sup-
porting the usefulness of a continuous MetS risk score,
instead of the dichotomized MetS definition traditionally
used in case-control studies.
A significant corrected association between a CYP2C19
rs4244285 and the MetS score was clearly found. The less
frequent allele of this variant seems to be conferring ars16147, TPMT rs1142345). A- Influence of the number of risk
umber of genetic risk factors (ANOVA for trend P < 0.001).
umber of risk genotypes, considering sufficient the presence of one
associated SNPs previous reported: CYP2C19 rs4244285, GABRA2
types for the 4 SNPs were identified in this population.
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http://www.dmsjournal.com/content/6/1/23protective effect to MetS susceptibility. In addition, we
found that these differences remained significant after ad-
justment for age, gender, smoking status, excessive alcohol
consumption and physical inactivity. We hypothesize that
CYP2C19 rs4244285 is involved in a common pathway,
the deregulation of which, in addition to other specific
genetic factors, may lead to the different MetS associated
traits. This hypothesis is supported by the fact that no as-
sociation was found between this SNP and each quantita-
tive risk factor. Other variants in GABRA2, NPY and
TPMT might represent additive genetic factors of modest
effect that should be taken into consideration to under-
stand the complete etiology of MetS, as well as environ-
mental factors such as smoking status, diet and physical
activity. Despite the need of further studies to confirm this
association in a larger population with better statistical
power, we are confident that these results will lead to the
identification of new therapeutic targets. These may be
useful in the treatment of the different clustered traits in-
stead of treating them individually and consequently im-
proving the outcome of patients affected by both MetS
and associated chronic diseases.
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